Cargando…

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

Aminopeptidases like aminopeptidase N (APN, also known as CD13) play an important role not only in normal cellular functioning but also in the development of cancer, including processes like tumor cell invasion, differentiation, proliferation, apoptosis, motility, and angiogenesis. An increased expr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wickström, Malin, Nygren, Peter, Larsson, Rolf, Harmenberg, Johan, Lindberg, Jakob, Sjöberg, Per, Jerling, Markus, Lehmann, Fredrik, Richardson, Paul, Anderson, Kenneth, Chauhan, Dharminder, Gullbo, Joachim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630444/ https://www.ncbi.nlm.nih.gov/pubmed/29029544 http://dx.doi.org/10.18632/oncotarget.18420

Ejemplares similares

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
por: Strese, Sara, et al.
Publicado: (2016)

In vitro and in vivo activity of melflufen (J1)in lymphoma
por: Delforoush, Maryam, et al.
Publicado: (2016)

Preclinical activity of melflufen (J1) in ovarian cancer
por: Carlier, Charlotte, et al.
Publicado: (2016)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines
por: Schepsky, Alexander, et al.
Publicado: (2020)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
por: Byrgazov, Konstantin, et al.
Publicado: (2020)

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
por: Bringhen, Sara, et al.
Publicado: (2021)

Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
por: Lindberg, Jakob, et al.
Publicado: (2021)

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
por: Fryknäs, Mårten, et al.
Publicado: (2013)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
por: Miettinen, Juho J., et al.
Publicado: (2021)

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
por: Schjesvold, Fredrik H, et al.
Publicado: (2022)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index
por: Hu, Kefei, et al.
Publicado: (2010)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES
por: Miettinen, Juho, et al.
Publicado: (2023)

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation
por: Karlsson, Henning, et al.
Publicado: (2019)

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen
por: Gebraad, Arjen, et al.
Publicado: (2022)

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
por: Flanagan, Ken, et al.
Publicado: (2022)

Effects of hypoxia on human cancer cell line chemosensitivity
por: Strese, Sara, et al.
Publicado: (2013)

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
por: Karlsson, Henning, et al.
Publicado: (2017)

P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS
por: Miguel, Enrique Maria Ocio San, et al.
Publicado: (2023)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
por: Larocca, Alessandra, et al.
Publicado: (2021)

Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia
por: Hallböök, Helene, et al.
Publicado: (2011)

Cell-Surface Peptidases
por: Mentlein, Rolf
Publicado: (2004)

Iron chelators target both proliferating and quiescent cancer cells
por: Fryknäs, Mårten, et al.
Publicado: (2016)

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
por: Schjesvold, F, et al.
Publicado: (2023)

Perivascular Neuropilin‐1 expression is an independent marker of improved survival in renal cell carcinoma
por: Morin, Eric, et al.
Publicado: (2020)

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response
por: Aiken, Robert, et al.
Publicado: (2017)

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
por: Eriksson, A, et al.
Publicado: (2015)

A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis
por: Sjöberg, Elin, et al.
Publicado: (2018)

Current and Novel Alkylators in Multiple Myeloma
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles
por: Rickardson, L, et al.
Publicado: (2005)

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
por: Selvin, Tove, et al.
Publicado: (2023)

Characterization of a highly conserved MUC5B-degrading protease, MdpL, from Limosilactobacillus fermentum
por: Leo, Fredrik, et al.
Publicado: (2023)

Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
por: Chauhan, Dharminder, et al.
Publicado: (2011)

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
por: Ek, Frida, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3646dcstuhrkrn6r2ahe3b2n9b